Showing results (81-90 of 150) with videos related to
Sort By:
Pageof 15
In Vivo (Athens, Greece)|March 4, 2022
The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast CancerPiero Fregatti, Marco Gipponi, Giulia Atzori, et al.British Journal of Cancer|January 13, 2017
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancerFederica Marmorino, Lisa Salvatore, Cecilia Barbara, et al.Annals of Surgical Oncology|May 13, 2022
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical TrialCorrado Tinterri, Damiano Gentile, Wolfgang Gatzemeier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplificationBruno De Bernardi, Mary Gerrard, Luca Boni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM TrialMarcello Tiseo, Luca Boni, Francesca Ambrosio, et al.BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.The New England Journal of Medicine|October 23, 2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Gianluca Masi, et al.The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 4, 2017
Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric ToolsLaura Biganzoli, Anna Rachelle Mislang, Samantha Di Donato, et al.The Oncologist|January 22, 2026
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT)Lorenzo Antonuzzo, Daniele Lavacchi, Francesca Spada, et al.The Lancet. Oncology|September 5, 2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, et al.Pageof 15